Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00041) | |||||
---|---|---|---|---|---|
Name |
Apremilast
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Apremilast; 608141-41-9; OTEZLA; CC-10004; CC 10004; Apremilast (CC-10004); CC10004; UNII-UP7QBP99PN; (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide; CHEBI:78540; UP7QBP99PN; CHEMBL514800; N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide; (S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione; C22H24N2O7S; Apremilast [USAN:INN]; apremilastum; MFCD18782607; HSDB 8221; Otezla (TN); Apremilast (JAN/USAN); Apremilast/CC 10004/; SCHEMBL302992; GTPL7372; EX-A336; QCR-202; cas:608141-41-9;Apremilast; AOB87775; BCP03783; BCP25283; BDBM50248919; ZINC30691736; AKOS016339660; BCP9000311; CCG-269336; CS-0671; DB05676; FK-0727; SB16492; AC-27650; HY-12085; BCP0726000109; AB0093139; SW219856-1; A11289; D08860; S-7765; Q2858961; UNII-N5UK68MGDZ component IMOZEMNVLZVGJZ-QGZVFWFLSA-N; (+)-N-(2-((1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4-yl)acetamide; (S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione(Apremilast); (S)-N-{2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}-acetamide; 4-[[5 pound not7-dihydroxy-2 pound not2-dimethyl-8-(2-methylpropanoyl)chromen-6-yl]methy l]-3 pound not5-dihydroxy-6 pound not6-dimethyl-2-(2-methylpropanoyl)cyclohexa-2 pound not4-dien- 1-one; Acetamide, N-(2-((1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)- 2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl)-; N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide; N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methanesulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide; N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Psoriasis vulgaris | ICD-11: EA90 | [1] | ||
PubChem CID | |||||
Formula |
C22H24N2O7S
|
||||
Canonical SMILES |
CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
|
||||
InChI |
1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1
|
||||
InChIKey |
IMOZEMNVLZVGJZ-QGZVFWFLSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=11561674"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 460.5 | Topological Polar Surface Area | 128 | |
XlogP | 1.8 | Complexity | 825 | ||
Heavy Atom Count | 32 | Rotatable Bond Count | 8 | ||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Apremilast 30 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Celgene Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.